Akebia Ther (AKBA) financial statements

Healthcare · Drug Manufacturers - Specialty & Generic · Market cap $193M

Akebia Ther reported revenue of $236M in fiscal 2025, up 75.0% a year over 9 years.

Net income was -$5M and the operating margin 9.9%, against -8889.9% in 2016.

Free cash flow was $68M.

The diluted share count rose 582% over the period (dilution).

Revenue and free cash flow

Fiscal years, $ billions.

-0.4-0.200.20.42016201720182019202020212022202320242025RevenueFree cash flow
Embed this chart

Free to use in articles and newsletters with the source line. Paste this HTML:

Income statement

Fiscal years, from Akebia Ther's 10-K filings with the SEC.

Fiscal year2016201720182019202020212022202320242025
Revenue$2M$181M$208M$335M$295M$212M$292M$195M$160M$236M
Cost of revenue——$8M$145M$296M$151M$86M$74M$63M$39M
Gross profit——$200M$190M-$2M$61M$207M$120M$97M$197M
Research and development$116M$231M$291M$323M$218M$148M$130M$63M$38M$62M
Selling, general and admin$22M$27M$87M$149M$154M$174M$139M$100M$107M$107M
Operating income-$136M-$77M-$178M-$286M-$378M-$265M-$81M-$46M-$50M$23M
Pre-tax income-$136M-$74M-$172M-$286M-$385M-$282M-$94M-$52M-$69M-$4M
Income tax——-$28M-$7M$0$0$0$0$0$2M
Net income-$136M-$74M-$144M-$280M-$385M-$282M-$94M-$52M-$69M-$5M
EPS (diluted)-$3.60-$1.69-$2.47-$2.36-$2.78-$1.70-$0.52-$0.28-$0.33-$0.02
Diluted shares38M44M58M118M138M166M183M187M211M257M
Gross margin——96.3%56.6%-0.6%28.8%70.7%61.9%60.6%83.3%
Operating margin-8889.9%-42.3%-85.8%-85.5%-128.2%-125.0%-27.6%-23.8%-31.5%9.9%
Net margin-8843.5%-40.7%-69.1%-83.5%-130.6%-133.3%-32.2%-26.7%-43.3%-2.3%

Balance sheet

Fiscal years, from Akebia Ther's 10-K filings with the SEC.

Fiscal year2016201720182019202020212022202320242025
Cash and short-term investments$260M$318M$322M$148M$269M$150M$90M$43M$52M$185M
Receivables$34M$34M$17M$39M$27M$52M$40M$39M$34M$47M
Inventory——$114M$116M$61M$37M$22M$16M$16M$16M
Total current assets$296M$358M$468M$310M$371M$271M$185M$118M$114M$253M
Property, plant and equipment$3M$4M$8M$10M$9M$7M$5M$4M$2M$1M
Goodwill——$55M$55M$55M$59M$59M$59M$59M$59M
Total assets$300M$364M$997M$771M$644M$529M$356M$242M$221M$377M
Total current liabilities$114M$141M$266M$208M$187M$261M$130M$100M$81M$163M
Long-term debt———$76M$96M$0$34M$17M$39M$48M
Total liabilities$232M$242M$361M$376M$397M$455M$351M$272M$270M$344M
Shareholders' equity$68M$123M$636M$393M$244M$74M$5M-$31M-$49M$33M
Net debt-$187M-$70M-$90M-$72M-$132M-$52M-$24M-$8M-$13M-$137M

Cash flow

Fiscal years, from Akebia Ther's 10-K filings with the SEC.

Fiscal year2016201720182019202020212022202320242025
Operating cash flow$58M-$56M-$97M-$257M-$110M-$253M-$73M-$23M-$41M$68M
Capital spending$3M$2M$2M$7M$317,000$59,000$114,000$0$33,000$291,000
Free cash flow$55M-$58M-$99M-$264M-$111M-$253M-$73M-$23M-$41M$68M
Stock-based compensation$6M$9M$19M$12M$24M$23M$18M$9M$8M$11M
Net borrowing——$0$78M$20M$0$0-$32M$8M$10M
Free cash flow margin3599.0%-31.9%-47.7%-78.8%-37.6%-119.5%-25.1%-12.0%-25.4%28.7%
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for AKBA.
Open AKBA in Investingly

Questions

What was Akebia Ther's revenue in 2025?

$236M in fiscal 2025, from its 10-K filing.

How much free cash flow does Akebia Ther generate?

$68M in fiscal 2025 (operating cash flow minus capital spending).

From Akebia Ther's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.